Insmed, Inc. $INSM Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC trimmed its holdings in Insmed, Inc. (NASDAQ:INSM) by 85.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,801 shares of the biopharmaceutical company’s stock after selling 38,688 shares during the period. ProShare Advisors LLC’s holdings in Insmed were worth $684,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of INSM. ORG Partners LLC boosted its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares during the last quarter. Hilltop National Bank purchased a new position in Insmed in the 2nd quarter worth approximately $28,000. FNY Investment Advisers LLC acquired a new position in shares of Insmed during the 2nd quarter worth approximately $33,000. LRI Investments LLC acquired a new position in shares of Insmed during the 2nd quarter worth approximately $59,000. Finally, Signaturefd LLC grew its position in shares of Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 325 shares in the last quarter.

Insmed Price Performance

NASDAQ:INSM opened at $201.62 on Wednesday. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $203.65. The stock’s fifty day moving average is $164.45 and its two-hundred day moving average is $122.82. The company has a market capitalization of $43.00 billion, a P/E ratio of -35.31 and a beta of 1.05. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same period in the previous year, the business posted ($1.27) earnings per share. The firm’s revenue for the quarter was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Mizuho set a $196.00 price objective on Insmed in a research report on Wednesday, October 29th. Royal Bank Of Canada raised their target price on Insmed from $139.00 to $215.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. lifted their price target on Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Wednesday, October 8th. Finally, Cowen restated a “buy” rating on shares of Insmed in a research report on Thursday, October 30th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $173.29.

Insider Buying and Selling at Insmed

In other news, Director Leo Lee sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $195.90, for a total value of $14,692,500.00. Following the sale, the director directly owned 54,677 shares of the company’s stock, valued at approximately $10,711,224.30. The trade was a 57.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director directly owned 262,675 shares of the company’s stock, valued at $38,190,318.25. The trade was a 3.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 252,922 shares of company stock valued at $43,533,383. 3.00% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.